By What Mechanisms Could Prothrombin Complex Concentrates Promote Factor VIII Bypassing Activity In Vivo?
- 31 August 1987
- journal article
- review article
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 1 (2) , 131-137
- https://doi.org/10.1016/s0887-7963(87)70013-3
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- The Regulation of Hemostasis: The Protein C SystemNew England Journal of Medicine, 1986
- Expression of active human factor VIII from recombinant DNA clonesNature, 1984
- Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.Journal of Clinical Investigation, 1983
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980
- Ineffectiveness of Certain Commercial Prothrombin Complex Concentrates in Treatment of Patients with Inhibitors of Factors VIII and IXNew England Journal of Medicine, 1979
- Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophilic patients with antibodies.Journal of Clinical Pathology, 1978
- CLOTTING FACTOR CONCENTRATES FOR RESISTANT HAEMOPHILIABritish Journal of Haematology, 1978
- Evidence that ‘Activated’ Prothrombin Concentrates Enhance Platelet Coagulant ActivityBritish Journal of Haematology, 1978
- In Vitro Thrombogenicity Tests of Factor IX ConcentratesBritish Journal of Haematology, 1977